RE:more dodgy transparency moves
hmmmmmmmm wrote: Management has pulled the latest September presentation down off the Investor Page of the company's site.
Toatally normal behavior...
Good!
an update must be coming soon!
maybe the $1.5 B revenue opportunity will be revised upward for one or more of the following reasons:
-Higher rate of Severe Sepsis in 2023 vs 2017
- higher per cartridge price due to expanded label
- higher per cartridge price due to exceeding expectations
-worldwide EAA sales once/if FDA approved PMX
- stage two monetization of iDialco for the benefit of Spectral shareholders
- inclusion of Cdn market ( the only place , really, where shares trade)
- possible use of PMX to treat Covid patients suffering from gut dysbiosis, wherein endotoxins escape into the bloodstream and trigger a cytokine storm and then sepsis and then death.
- mounting kidney disease due to aging obese popultation, Covid organ damage, long Covid, increasing antibiotic resistance, declining and overworked ICU staff ( higher hospital acquired infections) etc
-etc.
MM